Stock 688163 SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Shanghai Serum Bio-Technology Co., Ltd.

Equities

688163

CNE1000059X8

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-05-19 pm EDT 		5-day change 1st Jan Change
14.53 CNY -1.69% Intraday chart for Shanghai Serum Bio-Technology Co., Ltd. -3.00% -27.31%
Apr. 26 Shanghai Serum Bio-Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Feb. 23 Shanghai Serum Bio-Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2022 2023
Capitalization 1 2,282 2,163
Enterprise Value (EV) 1 1,363 1,303
P/E ratio 33.5 x 55.5 x
Yield 3.56% 1%
Capitalization / Revenue 13.1 x 11.4 x
EV / Revenue 7.82 x 6.85 x
EV / EBITDA 21,165,668 x 26,400,150 x
EV / FCF 42.4 x -334 x
FCF Yield 2.36% -0.3%
Price to Book 2.04 x 1.99 x
Nbr of stocks (in thousands) 108,220 108,220
Reference price 2 21.09 19.99
Announcement Date 4/20/23 4/26/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023
Net sales 1 185.6 208.7 174.2 190.1
EBITDA - - 64.38 49.35
EBIT 1 78.71 81.51 50.45 33.22
Operating Margin 42.42% 39.06% 28.96% 17.47%
Earnings before Tax (EBT) 1 74.75 87.72 74.04 45.42
Net income 1 63.17 76.8 64.14 38.77
Net margin 34.04% 36.8% 36.81% 20.39%
EPS 2 0.7800 0.9500 0.6300 0.3600
Free Cash Flow 1 43.23 20 32.16 -3.902
FCF margin 23.29% 9.58% 18.46% -2.05%
FCF Conversion (EBITDA) - - 49.95% -
FCF Conversion (Net income) 68.42% 26.04% 50.14% -
Dividend per Share - 0.9000 0.7500 0.2000
Announcement Date 2/17/22 2/17/22 4/20/23 4/26/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023
Net Debt 1 - - - -
Net Cash position 1 118 167 920 861
Leverage (Debt/EBITDA) - - - -
Free Cash Flow 1 43.2 20 32.2 -3.9
ROE (net income / shareholders' equity) 20% 23.1% 8.6% 3.51%
ROA (Net income/ Total Assets) 14.5% 14.2% 4.03% 1.81%
Assets 1 434.9 539.9 1,593 2,143
Book Value Per Share 2 3.630 4.560 10.40 10.00
Cash Flow per Share - 0 4.770 1.390
Capex 1 17.9 27.6 26.5 28.7
Capex / Sales 9.66% 13.23% 15.19% 15.08%
Announcement Date 2/17/22 2/17/22 4/20/23 4/26/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Biopharmaceuticals

1st Jan change Capi.
SHANGHAI SERUM BIO-TECHNOLOGY CO., LTD. Stock Shanghai Serum Bio-Technology Co., Ltd.
-27.31% 221M
CSL LIMITED Stock CSL Limited
-3.05% 90.45B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+3.95% 41.45B
BIOGEN INC. Stock Biogen Inc.
-10.63% 33.57B
UCB Stock UCB
+60.58% 25.73B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-20.68% 14.73B
INCYTE CORPORATION Stock Incyte Corporation
-8.97% 12.82B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-11.46% 11.7B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-43.05% 11.44B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+5.17% 8.79B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. 688163 Stock
  4. Financials Shanghai Serum Bio-Technology Co., Ltd.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW